All News

EULAR meeting room

Psoriatic Arthritis: EULAR 2026 Recap

Jack Cush, MD

Years of IL-17 vs. IL-23 debate in PsA finally got tested head-to-head: bimekizumab outperformed risankizumab on joint outcomes in the BE BOLD trial, while a GLP-1 combination study suggests weight and metabolic status are active drivers of PsA — not just comorbidities. This recap also digs into early signals that biologic choice may influence whether psoriasis progresses to PsA, and why some well-controlled patients are still in pain.

Read Article
vitamins.png

ACP Position Paper on Dietary Supplements

Jack Cush, MD

More than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law lets supplements reach the market with no premarket safety evaluation, unlike drugs or food additives.

Read Article
RheumNow Podcast square

Gout Cavalcade (7.10.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.

Read Article
uricacid.jpg

ICYMI: Worldwide Trends in Hyperuricemia

Jack Cush, MD

A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates

Read Article
GLP-1.pink

EULAR26: GLP-1 Agonist Use in the RISE Registry

EurekAlert!

At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). 

Read Article
morbidity,covid,heart,lung,brain

Spotlight on Comorbidities from EULAR 2026

EurekAlert!

Systemic autoimmune diseases are associated with increased cardiovascular morbidity and mortality – possibly through autonomic imbalance, myocardial inflammation, or fibrotic infiltration of the conduction system. A team in Colombia have been looking into the risk of

Read Article
SGLT2i use in gout reduces use of gout meds. Study of 26,739 gout pts w/ NIDDM (mean 66 yrs), 67% w/ polypharmacy. SGLT2i (vs DPP-4i) user had less Allopurinol starts (HR 0.62;0.52–0.73), also lower use of steroids (,78), NSAID (.85), colchicine (.87) & diuretics (.87) https://t.co/1dW27YzSvg
Dr. John Cush RheumNow ( View Tweet)
GI dz & malnutrition in scleroderma (SSc) is common, assessed by BMI. Among 450 SSc (F/U 5.3 yrs), lower BMI were significantly assoc w/ pseudoobstruction, smaller oral aperture, higher Medsger vascular severity scores. Defines those at risk https://t.co/w45OhUOUTh https://t.co/hWuIaS6OUe

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout in Minority Populations Recent research has revealed substantial racial and ethnic disparities in both who develops gout and the care patients receive. These differences reflect not only genetic susceptibility but also the substantial influence of social determinants of https://t.co/SKEsQVZPw6
Dr. John Cush RheumNow ( View Tweet)
ACP Position Paper on Dietary Supplements More than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law allows supplements to reach the market without a premarket safety evaluation, unlike https://t.co/gwLG4ElfCq
Dr. John Cush RheumNow ( View Tweet)
Why Do Gout Flares Start at Night? The striking propensity for gout flares to initiate at night has been recognized for centuries. More recent epidemiological research supports this observation, indicating that the risk of a gout flare is more than twice as high in the early https://t.co/FbCUmXEl2y
Dr. John Cush RheumNow ( View Tweet)
Weight loss helps gout, but extreme weight loss (bariatric surgery, ketogenic diets) may trigger gouty attacks. (Not seen with GLP-1 agonist weight loss) For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/LGEENexSZ6

Links:

Dr. John Cush RheumNow ( View Tweet)
Long term F/U of Gout (CARES) trial (febuxostat vs allopurinol) shows remission increased from 37% (1,593/4,259) 1st Yr to 63% (322/510) at year 6. Over the 6 years, ~60 achieved remission at least once; more likely based on age, race, dz severity, comorbidities, & febuxostat

Dr. John Cush RheumNow ( View Tweet)

EULAR26: GLP-1 Agonist Use in the RISE Registry At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). https://t.co/EqgETKjN1v
Dr. John Cush RheumNow ( View Tweet)
20% sample of elder RA Medicare pts (2009-2022) on TNFi who either stopped or tapered TNFi found 38% sustained de-escalation, while 62% re-escalated within a medianof 164. Re-escalation was more likely in Blacks, Hispanic/other, with a lower comorbidity burden. https://t.co/rEB3VdOii2
Dr. John Cush RheumNow ( View Tweet)
Dietary Interventions in PsA Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050. https://t.co/VLldzkbFU3 https://t.co/5w5wstPawk

Links:

Dr. John Cush RheumNow ( View Tweet)
Risk of Psoriasis is increased 19% by long-term exposure to Particulate Matter (PM2.5 & PM10; adjHR 1.19), while short-term exposure increases risk of psoriasis exacerbation (adjusted OR 1.03). Stronger in younger, urban, lower SES, ever-smokers, & comorbid allergies https://t.co/pd6S13RG1B
Dr. John Cush RheumNow ( View Tweet)
Do u screen your SLE pts for OP? In this real-world multicenter study, SLE pts who were likely to be tested for BMD were older, had MSK s/sxs, sSJg & longer GC exposure. RFs for OP: LN, higher dse. activity, longer GC use, high cumulative GC dose POS1372 @RheumNow #EULAR2026 https://t.co/pAxhOPGGYs

Links:

sheila RHEUMarampa ( View Tweet)
#OP0207 #EULAR2026: SUPERFIBRES trial suggests dietary fibre supplementation may enhance MTX response in RA. Inulin improved EULAR responses and Th17/Treg balance over 30 days, with strongest effects seen in MTX-treated patients. Fascinating microbiome-linked signal. @RheumNow https://t.co/nCvZlooamF

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA? Over 70% of patients with psoriatic arthritis (PsA) struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. https://t.co/pAIXkdazci https://t.co/vQTn3BWv2r

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×